Teens With Hidradenitis Suppurativa Now Have a New Treatment Option
My AccountFIND A DOCTORNewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSmileSun CareTreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin ConditionsSkin Lifting and TighteningBodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessFitnessGLP-1sHealthMenopauseNewBeauty RXBEAUTYPASSNewsView All NewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceView All FaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSmileSun CareTreatmentsView All TreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin ConditionsSkin Lifting and TighteningBodyView All BodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairView All HairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsView All AwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingView All ShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessView All WellnessFitnessGLP-1sHealthMenopauseNewBeauty RXLoading…FIND A DOCTORBEAUTYPASS Advertisement Home›Chronic Skin Conditions Teens With Hidradenitis Suppurativa Now Have a New Treatment Option For teens 12 and older with HS, this approval adds a biologic with a different mechanism to the treatment mix. Hidradenitis suppurativa often starts during the teenage years, but treatment options for younger patients have historically lagged years behind those available to adults. The FDA has approved secukinumab (Cosentyx) for moderate to severe HS in patients as young as 12 who weigh at least 30 kg, about 66 pounds. As reported by Dermatology Times, it’s the first IL-17A inhibitor, a drug class that targets a specific inflammatory protein tied closely to active HS, approved for this age group. Running a placebo-controlled trial in adolescent HS is difficult. The eligible patient pool is small, and withholding treatment from a teenager with a painful, scarring condition raises its own ethical questions. Instead of a pediatric trial, the approval relied on pharmacokinetic modeling: dosing data extrapolated from the adult HS trials that already support secukinumab, combined with pediatric dosing data from three other conditions where the drug is approved in younger…